title: Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever.
authors.affiliation: Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey. drsy75@gmail.com.
authors.forename: Sedat
authors.initials: S
authors.lastname: Yilmaz
authors.affiliation: Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey.
authors.forename: Muhammet
authors.initials: M
authors.lastname: Cinar
authors.affiliation: Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey.
authors.forename: Ismail
authors.initials: I
authors.lastname: Simsek
authors.affiliation: Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Erdem
authors.affiliation: Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey.
authors.forename: Salih
authors.initials: S
authors.lastname: Pay
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D010505:Familial Mediterranean Fever / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000276:immunology; D000685:Serum Amyloid A Protein / Q000378:metabolism*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; D000685:Serum Amyloid A Protein; C502936:tocilizumab